Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn’s disease, and clinical prognosis in inflammatory bowel disease

BMC Gastroenterology

Research Article

S. Anjani Mattai¹  Daniel Hommes²  Diana Hoang-Ngoc Tran²  Caroline C. Mussatto²  Wendy Ho²  Christine Shieh²  Precious Lacey²  Samantha Ho²  Christina Ha²  Guy Weiss²  Michelle Cheng²  Angelos Oikonomopoulos²  Hon Wai Koon³  Jiani Wang⁴ 

[1] Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, 90095, Los Angeles, CA, USA;Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California Los Angeles, 90095, Los Angeles, CA, USA;Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California Los Angeles, 90095, Los Angeles, CA, USA;Center for Inflammatory Bowel Diseases, Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, 43-152 Center for Health Sciences Building, 10833 Le Conte Avenue, 90095, Los Angeles, CA, USA;Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California Los Angeles, 90095, Los Angeles, CA, USA;Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China;

关键词: Biomarkers;    Complications of IBD;    Serologic testing;    Prognosis;    Mucosal disease activity;   

DOI  :  10.1186/s12876-017-0619-4

 received in 2017-02-09, accepted in 2017-04-20,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundCathelicidin (LL-37) is an antimicrobial peptide known to be associated with various autoimmune diseases. We attempt to determine if cathelicidin can accurately reflect IBD disease activity. We hypothesize that serum cathelicidin correlates with mucosal disease activity, stricture, and clinical prognosis of IBD patients.MethodsSerum samples were collected from two separate cohorts of patients at the University of California, Los Angeles. Cohort 1 consisted of 50 control, 23 UC, and 28 CD patients. Cohort 2 consisted of 20 control, 57 UC, and 67 CD patients. LL-37 levels were determined by ELISA. Data from both cohorts were combined for calculation of accuracies in indicating mucosal disease activity, relative risks of stricture, and odds ratios of predicting disease development.ResultsSerum cathelicidin levels were inversely correlated with Partial Mayo Scores of UC patients and Harvey-Bradshaw Indices of CD patients. Among IBD patients with moderate or severe initial disease activity, the patients with high initial LL-37 levels had significantly better recovery than the patients with low initial LL-37 levels after 6–18 months, suggesting that high LL-37 levels correlate with good prognosis. Co-evaluation of LL-37 and CRP levels was more accurate than CRP alone or LL-37 alone in the correlation with Mayo Endoscopic Score of UC patients. Low LL-37 levels indicated a significantly elevated risk of intestinal stricture in CD patients.ConclusionCo-evaluation of LL-37 and CRP can indicate mucosal disease activity in UC patients. LL-37 can predict future clinical activity in IBD patients and indicate risk of intestinal stricture in CD patients.

【 授权许可】

CC BY   
© The Author(s). 2017